Spiro-Cyclic Amine Derivatives for Selective S1P5 Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutics for treating age-related cognitive decline and dementia have not been successful in effectively modulating S1P receptors, particularly the S1P5 receptor, leading to a need for new compounds with selective agonist properties to address cognitive disorders.
Innovation Solution
Development of spiro-cyclic amine derivatives, such as Compound 1, which act as selective S1P5 receptor agonists, modulating the S1P signaling system to treat CNS disorders like age-related cognitive decline and dementia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapeutics are used to treat age-related cognitive decline, then treatment is provided, but they fail to effectively modulate S1P receptors particularly S1P5
Solution Approach 1:
The patent applies local quality by designing a compound with specific structural features (spiro-cyclic amine derivative with particular substituents at positions R1-R6) that confer selective affinity for the S1P5 receptor subtype. This localized molecular design ensures the compound interacts preferentially with S1P5 over other S1P receptor subtypes, resolving the contradiction between general S1P modulation and selective S1P5 targeting.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters of the spiro-cyclic amine structure (such as substituent types, positions, and configurations) to optimize both binding affinity and selectivity for S1P5 receptors. By adjusting these chemical parameters, the compound achieves reliable S1P5 modulation while maintaining therapeutic effectiveness for cognitive disorders.
2Adaptability or versatility
If non-selective S1P receptor modulators are used, then broad S1P signaling is affected, but cardiovascular and immunomodulatory side effects occur
Solution Approach 1:
The patent applies the extraction principle by isolating and targeting only the S1P5 receptor subtype through selective compound design, while excluding interaction with other S1P receptor subtypes (S1P1-S1P4) that mediate cardiovascular and immunomodulatory functions. This selective extraction of S1P5-specific activity eliminates harmful side effects while preserving beneficial cognitive effects.
Solution Approach 2:
The compound's molecular structure is locally optimized to interact specifically with S1P5 receptors in the central nervous system, avoiding binding to S1P1, S1P2, S1P3, and S1P4 receptors that are expressed in cardiovascular and immune tissues. This localized receptor specificity prevents systemic side effects while maintaining central nervous system therapeutic effects.
3Ease of manufacture
If current therapeutics are developed for cognitive disorders, then treatment approaches are provided, but successful candidates have not been achieved
Solution Approach 1:
The patent applies parameter changes by optimizing multiple molecular parameters of the spiro-cyclic amine derivative simultaneously to achieve the desired balance between pharmacological activity, selectivity, and drug-like properties. This systematic parameter optimization has resulted in a successful therapeutic candidate that addresses age-related cognitive decline, overcoming the failures of previous approaches.
Data Source
AI summary
The present invention is directed to spiro-cyclic amine derivatives which are modulators of S1P receptors and are useful in the treatment of CNS disorders.